La cadena de opciones muestra datos clave de las opciones de acciones de Cartesian Therapeutics a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Cartesian Therapeutics..

Cartesian Therapeutics (NASDAQ:RNAC) Bolsa, Cadena de Opciones

CARTESIAN THERAPEUTICS INC

Cartesian Therapeutics

Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company. The company uses its ImmTOR immune tolerance platform, which is designed to give rise to antigen-specific immunity, mitigating unwanted immune responses. The company leverages its proprietary technology and manufacturing platform to introduce one or more mRNA molecules into cells to enhance their function.

Movimiento de acciones

AEHL

AMBC

BTOG

CCCS

DGICA

EHAB

FFIC

FMTO

IXHL

RNAC

SDHC

SVRE

TNMG

VERO

VINC

VNOM

WORX

Acciones en alza y en caída antes del mercado: descubre qué impulsó los mayores movimientos bursátiles del día.

Acciones de Venus Concept (VERO) se disparan un 200%; aquí están 20 acciones que se mueven en premercado

Movers_Stocks

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

ADPT

CXAI

ENTO

HRTG

IIIN

LION

LSAK

MLNK

MULN

OLMA

SGMO

SHCO

SLSR

Sangamo Therapeutics se dispara tras anunciar un acuerdo exclusivo con Eli Lilly sobre tecnología genética patentada. ¿Qué implica esto?

Acciones de Sangamo Therapeutics (SGMO) se disparan un 40%; Aquí están 20 acciones que se mueven en premercado

Cartesian Therapeutics, Inc. - Common Stock

Cartesian Therapeutics Inc

WIIM

ReNew Energy Global shares are trading higher after the company reported better-than-expected Q4 financial results.

OMS Energy Technologies Inc. ("OMS" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMSE#NASDAQ">OMSE</a>), a growth-oriented manufacturer of surface wellhead systems ("SWS") and oil country tubular goods ("OCTG") for the oil and gas industry, today provided a business update outlining its recent accomplishments as the Company prepares for its inaugural earnings call following its successful Nasdaq listing in May 2025.
Operational Highlights
<ul>
<li>New order win in Angola and renewed contract in Thailand; Southeast Asia emerging as driving force in customer acquisition</li>
<li>Expanding business footprint and growing talent pool</li>
<li>R&amp;D achievements and partnerships steadily enriching product portfolio</li>
<li>Consistent enhancements to occupational health, safety and environmental management</li>
<li>Development initiatives fostering revenue diversification and enhancing financial stability &nbsp;</li>
</ul>
Mr. How Meng Hock, CEO of OMS Energy Technologies Inc., commented, "We're excited to begin our journey as a public company with a healthy operational foundation, underscored by thriving customer relationships and partnerships, an expanding brand presence and cutting-edge R&amp;D and manufacturing capabilities. We are also supported by a strong balance sheet and a deep commitment to prudent financial management, positioning us to quickly and flexibly execute our development strategy when suitable opportunities arise. With our focus on exceptional service and dedication to crafting superior products, we're confident of delivering innovative solutions to a growing, global customer base, creating value for all of our stakeholders."
Customer Growth and Diversification
Offering a broad array of highly engineered products and customizable solutions for the oil and gas industry, OMS is anchored by a solid base of long-term contracts and longstanding relationships with global and local oil companies, drilling contractors, E&amp;P and oilfield service providers across the Asia Pacific, Middle East and North Africa (MENA), and West African regions. The Company recently entered the Angola market and has secured a letter of award through its Middle East representative for the supply of surface wellhead systems to Grupo Simples Oil in the Onshore Kwanza Basin Block of KON-06 in Angola, expanding its brand presence in West Africa.
In the Indonesian market, the Company's marketing efforts are attracting new customers, such as PT Seleraya Belida (South Sumatra) and Pertamina Hulu Sanga Sanga (East Kalimantan), and driving steady growth in sales of surface wellhead and Christmas tree products.
OMS' existing customer base continues to exhibit strong loyalty. In June, PTTEP, a long-term customer in the Thailand market, signed a new three-year agreement effective July 1, 2025, further stabilizing the Company's revenue base. The Company also inked a 10-year supply agreement with Saudi Aramco in early 2024, projected to generate an estimated $120 to $200 million annually. Moreover, the Company's annual price agreement with Halliburton continues to fuel robust order volumes at its Malaysia and Singapore facilities.
Geographic and Talent Pool Expansion
OMS boasts a broad geographic footprint in the oil-rich Asia Pacific and MENA regions, with 11 manufacturing facilities strategically situated across six countries (Singapore, Malaysia, Brunei, Saudi Arabia, Thailand, and Indonesia). By hiring local citizens, producing products and services within these jurisdictions, and sourcing high-value materials locally, the Company establishes eligibility to participate in government tenders and contracts, boosting its competitive edge. Employing locals also helps the Company meet the requirements of localization programs such as IKTVA in Saudi Arabia and TKDN in Indonesia while enriching its talent pool. The Company is exploring new operating jurisdictions to increase market share and extending its reach globally through a growing number of export countries.
Product Development &amp; Manufacturing Advancements
OMS's $1.1 million investment in Additive Manufacturing (AM) research is propelling progress in the development of a metallic seal for the Company's high-pressure-high temperature (HPHT) gate valves, a technological breakthrough that promises to promote innovation, improve supply chain efficiency and enable better material selection for critical components. To date, OMS has completed Phase 1 of its proof of concept, covering material selection, additive manufacturing methodology and stress analysis on the part for fit, form and function for using this method. The Company continues to invest in R&amp;D, forging partnerships with top institutions such as the Singapore Institute of Manufacturing and Technology (SIMTech) to remain at the forefront of industry innovation.
Meanwhile, the Company is steadily delivering on orders placed under its long-term agreements with Saudi Aramco and Halliburton Malaysia and Singapore, leveraging its precision manufacturing expertise and strategically-located facilities to produce mission-critical products and custom solutions with shorter lead times. A healthy, balanced manufacturing capacity utilization level empowers OMS to seamlessly meet rising demand from new and existing customers.
Occupational Health, Safety and Environmental Management Enhancements
Safety and environmental protection are critical to the oil and gas industry and a key cornerstone of OMS' operations. The Company holds ISO 9001 and API Q1 quality management system certifications for all of its manufacturing sites, as well as ISO 45001-Occupational Health and Safety Management System and ISO 14001-Environmental Management System certifications. The Company recently completed the annual surveillance audit required to maintain its ISO 45001 and ISO 14001 certifications, a crucial step in the Company's ongoing implementation of ESG programs.
Strategic Development Initiatives
Sustainable, long-term growth remains OMS' top priority. The Company's R&amp;D collaboration with Singapore's Agency for Science, Technology and Research (A&#x2A;STAR) and SIMTech reflects its commitment to environmental sustainability, covering life cycle analysis, energy efficiency monitoring and digital transformation and innovation. OMS is also actively exploring growth and revenue diversification through acquisitions, joint ventures and strategic alliances. By driving development both organically and externally, OMS is creating a more resilient and balanced portfolio, strengthening the backbone of its business.

OMSE

OMS Energy Technologies Highlights Expanding Footprint In Southeast Asia, Advancements In R&D And Manufacturing, Strategic Partnerships, And Commitment To Safety, ESG, And Global Growth Ahead Of First Earnings Call Post-Nasdaq Listing

UBS analyst Bryan Adams initiates coverage on Freshpet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FRPT#NASDAQ">FRPT</a>) with a Sell rating and announces Price Target of $65.

Price Target

Initiation

Analyst Ratings

FRPT

UBS Initiates Coverage On Freshpet with Sell Rating, Announces Price Target of $65

Actelis Networks, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASNS#NASDAQ">ASNS</a>) ("Actelis" or the "Company"), a market leader in cyber-hardened, rapid deployment networking solutions for IoT and broadband applications, today announced that it is accelerating its federal and military market expansion initiatives. As part of this strategic push, the Company is pleased to announce that it has hired Mr. Jason Chasse as full-time Director of Federal Sales. Actelis has a long history serving as a trusted partner to major military and federal agencies and believes the Company is uniquely positioned to capitalize on major opportunities in the sector.

ASNS

Actelis Networks Accelerates Federal And Military Market Expansion Initiatives

Harvard University will urge a federal judge Monday to block President Donald Trump&#8216;s proclamation barring foreign nationals from studying at the institution. According to Reuters, U.S. District Judge Allison Burroughs will consider extending a temporary restraining order during a Boston hearing as the university challenges restrictions affecting 6,800 international students.
What Happened: Trump signed a proclamation June 5 suspending entry of foreign nationals to study at Harvard for six months, citing national security concerns. The directive claimed Harvard has &#8220;extensive entanglements with foreign adversaries&#8221; and &#8220;concerning foreign ties and radicalism.&#8221; International students comprise<a href="https://www.benzinga.com/25/05/45671848/kevin-oleary-says-international-students-are-extraordinary-individuals-he-adds-they-dont-hate-america-and-i-want-to-invest-in-them"> 27% of Harvard&#8217;s enrollment</a>, with China and India as top origin countries.
Judge Burroughs issued a temporary restraining order June 6 preventing implementation while Harvard&#8217;s lawsuit proceeds. The university filed two separate legal challenges seeking to unfreeze $2.5 billion in federal funding and prevent international student restrictions. 
The administration has <a href="https://www.benzinga.com/news/politics/25/06/45879240/secretatry-of-state-marco-rubio-pushes-sanctions-probe-into-harvard-over-ties-to-blacklisted-chinese-entity-report">frozen $3 billion in Harvard grants</a> and proposed ending the university&#8217;s tax-exempt status. Homeland Security Secretary Kristi Noem revoked Harvard&#8217;s Student and Exchange Visitor Program certification May 22, but Burroughs temporarily blocked that action.
Secretary of State Marco Rubio is pursuing a federal sanctions investigation into Harvard over alleged violations involving a blacklisted Chinese entity. Trump&#8217;s proclamation instructs Rubio to consider revoking current students&#8217; visas and allows extensions beyond six months.
Harvard argues the administration is retaliating for the university&#8217;s refusal to accept federal demands controlling governance, curriculum, and faculty ideology, violating First Amendment protections. The Justice Department contends Trump&#8217;s proclamation should be considered separately from previous actions. See Also: <a href="https://www.benzinga.com/markets/tech/25/06/45945298/tesla-model-3-on-fsd-mode-struck-by-train-after-getting-trapped-on-railroad-tracks-report">Tesla Model 3 On FSD Mode Struck By Train After Getting Trapped On Railroad Tracks: Report</a>
Why It Matters: The administration has revoked over 1,500 student visas across 222 schools nationwide, creating institutional uncertainty. International students contribute $44 billion annually to the U.S. economy and support 378,000 jobs. Japan&#8217;s Education Minister <a href="https://www.benzinga.com/news/legal/25/06/45786819/trump-suspends-entry-of-foreign-students-to-harvard-for-six-months-citing-national-security-university-calls-move-illegal-retaliatory-step">announced universities would welcome displaced Harvard students</a>, including 110 Japanese nationals currently enrolled. The legal outcome could establish precedent for federal authority over university international programs and First Amendment protections in higher education.
Image via Shutterstock Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/fda/25/06/45945282/sarepta-therapeutics-stock-plummets-over-40-on-second-fatal-case-linked-to-its-gene-therapy">Sarepta Therapeutics Stock Plummets Over 40% On Second Fatal Case Linked To Its Gene Therapy</a> Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.</li>
</ul>

Politics

Harvard To Ask Judge To Extend Block On Trump's Foreign Student Ban,  Citing Retaliation And Free Speech Violations

Smurfit WestRock shares are trading higher after Jefferies upgraded the stock from Hold to Buy and raised its price target from $44 to $55.

NRx Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NRXP#NASDAQ">NRXP</a>) ("NRx Pharmaceuticals", "NRx" or the "Company"), a clinical-stage biopharmaceutical company, and HOPE Therapeutics, Inc., ("HOPE," or the "Company"), a multi-site clinical care delivery organization and wholly-owned subsidiary of NRx, today announced a strategic investor relations partnership with&nbsp;astr partners, a boutique investor relations and capital advisory firm focused on the life sciences sector.

NRXP

NRx Pharmaceuticals And HOPE Therapeutics Announce Strategic Investor Relations Partnership With Life Sciences Advisory Firm Astr Partners

SUNation Energy, Inc. (NASDAQ:<a href="https://www.benzinga.com/stock/SUNE#NASDAQ">SUNE</a>) ("the Company"), a leading provider of sustainable solar energy and backup power solutions for households, businesses, and municipalities, today announced that, by a decision dated June 10, 2025, the Nasdaq Hearings Panel (the "Panel") made a finding that the Company is not in violation of Nasdaq Listing Rules 5100 and 5550(a)(2), the "Public Interest Concern" and "Bid Price Rule", respectively, which were the bases of the non-compliance and delisting notices previously provided to and disclosed by the Company.
Accordingly, the Company is deemed to be in full compliance with the applicable Nasdaq Listing Rules, and the Panel granted the Company's request for continued listing on The Nasdaq Stock Market LLC ("Nasdaq") and is closing this matter.

SUNE

SUNation Energy Secures Nasdaq Compliance After Panel Finds No Rule Violations

CELH

Celsius Holdings shares are trading higher after TD Cowen upgraded the stock from Hold to Buy and raised its price target from $37 to $55.

UBS analyst Bryan Adams initiates coverage on Conagra Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAG#NYSE">CAG</a>) with a Neutral rating and announces Price Target of $22.

UBS Initiates Coverage On Conagra Brands with Neutral Rating, Announces Price Target of $22

JMP Securities analyst Nicholas Jones downgrades Angi (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANGI#NASDAQ">ANGI</a>) from Market Outperform to Market Perform.

Downgrades

ANGI

JMP Securities Downgrades Angi to Market Perform

INCY

Incyte shares are trading higher after the company announced a collaboration with QIAGEN to develop a novel diagnostic panel to support its portfolio of investigational therapies for patients with myeloproliferative neoplasms. Also, the company announced first clinical data from two studies evaluating the safety, tolerability and efficacy of INCA033989.

The Phase 2 Istaroxime study was successful in multiple endpoints showing promise for how it may be utilized if approved in its targeted indications&nbsp;&nbsp;&nbsp;
Primary endpoint of the study was met of increasing systolic blood pressure and demonstration of other benefits including no increase in heart rate and preserved renal function
Partnership discussions with multiple potential partners that may fund the remainder of clinical development thus eliminating the Company's cash burn with the cardiovascular pipeline
Phase 2 SEISMiC C interim data results targeted for July
Final stages of protocol design for Phase 3 in acute heart failure indication for China nearly complete for regional license partner and will be fully funded by the licensee
WARRINGTON, Pa., June 16, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. ("Windtree" or the "Company") (NasdaqCM: WINT), a diversified company focused on revenue generation in multiple growing industries, announced that the istaroxime early cardiogenic shock Phase 2 study called SEISMiC B is published in the Journal of Heart and Lung Transplantation and is available on the journal website. The publication is entitled "Safety and Efficacy Intravenous Istaroxime up to 60 hours for Patients with Pre-Cardiogenic Shock.1" Patients with this condition have poor cardiac function, low blood pressure and need rapid treatment.
The article notes in the SEISMiC B study that istaroxime significantly increased blood pressure over the first six hours of treatment and persisted for 60 hours. Patients also had significantly improved cardiac output, decreased pulmonary capillary wedge pressure (a measure of fluid back up), no increase in heart rate, no increase in clinically significant arrythmias and preserved renal function, a very unique profile of potential beneficial effects for this patient population.
An accompanying editorial highlighted the encouraging results and described istaroxime as, "a potential new approach to heart failure-cardiogenic shock in which the next frontier is not just survival, but earlier and smarter stabilization.2"
Istaroxime has completed four positive Phase 2 studies, including two in early cardiogenic shock (called SCAI Stage B). Market research conducted by the Company with U.S. based clinical cardiologists reveals a high desire for cardiogenic shock drug treatment innovation.

Biotech

General

WINT

Windtree Therapeutics' Istaroxime Achieves Success In Phase 2 SEISMiC B Study, Meeting Primary Endpoint And Showing Cardiogenic Shock Benefits Without Increasing Heart Rate Or Renal Risk

On CNBC's &#8220;<a href="https://www.cnbc.com/video/2025/06/13/final-trades-alphabet-unitedhealth-schlumberger-and-the-iye.html">Halftime Report Final Trades</a>,&#8221; Rob Sechan, CEO of NewEdge Wealth, recommended buying Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>). The stock has been the best performer in the Magnificent Seven over the past month and <a href="https://www.benzinga.com/markets/tech/25/06/45899809/ericsson-google-cloud-launch-new-tool-to-help-telecoms-build-faster-smarter-networks">is the cheapest as well.</a>
As per recent news, Ericsson announced on June 12 the launch of Ericsson On-Demand, a new solution delivering core network services as a true software-as-a-service (SaaS) platform to communications service providers (CSPs). The platform is designed with Alphabet Google Cloud, leveraging AI infrastructure and Google Kubernetes Engine (GKE), and is managed end-to-end by Ericsson.
Shannon Saccocia, CFA, is the chief investment officer of NB Private Wealth, named iShares U.S. Energy ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IYE#NYSE">IYE</a>) as her final trade.
Don't forget to check out our <a href="https://www.benzinga.com/premarket/">premarket coverage her</a>e
Sarat Sethi, DCLA managing partner and portfolio manager, picked Schlumberger Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLB#NYSE">SLB</a>) as his final trade.
On the earnings front, Schlumberger reported worse-than-expected first-quarter 2025 results on April 25. Revenue declined 3% year over year to $8.49 billion, missing estimates of $8.59 billion. Adjusted EPS slid 4% to 72 cents, missing the consensus of 74 cents.
Stephen Weiss, chief investment officer and managing partner of Short Hills Capital Partners, said UnitedHealth Group Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) is a good trade from here.
As per recent news, UnitedHealth Group re-elected all current directors on June 4. The board authorized the payment of a cash dividend of $2.21 per share, up from the prior dividend of $2.10, to be paid on June 24 to common stock shareholders of record as of the close of business on June 16.
Price Action:
<ul class="wp-block-list">
<li>Alphabet shares fell 0.6% to close at $174.67 on Friday.</li>
<li>iShares U.S. Energy ETF rose 1.8% during the session.</li>
<li>UnitedHealth shares fell 1.6% to settle at $313.53 on Friday.</li>
<li>SLB shares gained 1.9% to settle at $36.30 during the session.</li>
</ul>
Check This Out:<a href="https://www.benzinga.com/trading-ideas/short-ideas/25/06/45924005/top-2-energy-stocks-that-may-fall-off-a-cliff-in-june"> </a>
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/06/45924005/top-2-energy-stocks-that-may-fall-off-a-cliff-in-june">Top 2 Energy Stocks That May Fall Off A Cliff in June</a></li>
</ul>
Photo: Shutterstock

Media

GOOG

GOOGL

iShares Dow Jones US Energy Sector Index Fund

UnitedHealth Group, Schlumberger, Alphabet And More On CNBC's 'Final Trades'

Natural Gas Services Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NGS#NYSE">NGS</a>), a leading provider of natural gas compression equipment, technology, and services to the energy industry, today announced that Stephen C. Taylor has transitioned from Chairman of the Board to the role of Chairman Emeritus, effective immediately. Concurrently, the Company's Board of Directors has appointed Donald J. Tringali as Chairman. Mr. Taylor continues his role as a director on the Company's Board.

Management

Natural Gas Services Appoints Donald Tringali As Chairman; Says Stephen Taylor Transitioned From Chairman Of Board To Chairman Emeritus, Effective Immediately

Refinements to probe configuration and proprietary algorithms are expected to drive substantial improvements in MRI-PDFF correlation
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fendrainc.com%2F&amp;esheet=54274068&amp;newsitemid=20250616575045&amp;lan=en-US&amp;anchor=ENDRA+Life+Sciences+Inc.&amp;index=1&amp;md5=d3b8793be6994cca89b77baa3171adab">ENDRA Life Sciences Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDRA#NASDAQ">NDRA</a>), a pioneer in imaging technologies for the early detection and monitoring of metabolic liver disease, today announced that its ongoing multisite pilot study has helped to identify several product enhancements to further improve the performance of its TAEUS&#xAE; Liver system against the gold standard, MRI. These findings are expected to drive substantial improvements to the device's probe design and proprietary algorithms, measurably improving diagnostic accuracy and repeatability. These enhancements are currently being implemented and are expected to strengthen the outcomes of the Company's planned U.S. Food and Drug Administration ("FDA") De Novo pivotal study.
Consistent with its revamped go-to-market strategy, ENDRA is conducting a multisite clinical initiative designed to bolster the diagnostic performance of TAEUS Liver prior to initiation of the FDA pivotal study. In collaboration with several leading imaging centers, the Company has collected liver fat measurement data from more than 100 subjects that compare TAEUS scans against MRI-PDFF.

NDRA

ENDRA Life Sciences Announces That Its Ongoing Multisite Pilot Study Has Helped To Identify Several Product Enhancements To Further Improve The Performance Of Its TAEUS Liver System Against The Gold Standard, MRI

NITO

N2OFF Increases Investment In Melz Project To Explore Integrating Additional 40-60 MW Battery Storage

<ul>
<li>The test, run on Abbott's portable i-STAT&#xAE; Alinity&#xAE; instrument, uses whole blood to help evaluate patients with a suspected mild traumatic brain injury (mTBI), otherwise known as concussion</li>
<li>The test produces lab-quality results in 15 minutes</li>
<li>Clinicians can get a result at the patient's bedside, making the test accessible at urgent care clinics and healthcare settings outside of the hospital emergency room</li>
<li>The test can be used to help evaluate patients up to 24 hours after injury</li>
</ul>
MISSISSAUGA, ON, June 16, 2025 /CNW/ -- Abbott (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) announced today that Health Canada has approved the company's&nbsp;i-STAT TBI test cartridge for use with whole blood, helping clinicians to assess suspected concussion at the patient's bedside and obtain lab-quality results in 15 minutes. Previously, the tests used to help assess mild traumatic brain injury (mTBI) were only authorized for use with plasma or serum, requiring samples to be sent to a lab for processing.

Health Canada Approves Abbott's i-STAT TBI Test Cartridge For Use With Whole Blood, To Assess Suspected Concussion At Patient's Bedside And Obtain Lab-Quality Results In 15 Minutes

Achievement demonstrates manufacturer's drive for excellence in drone production&nbsp;
Cheseaux-sur-Lausanne, Switzerland, June 16, 2025 (GLOBE NEWSWIRE) -- AgEagle Aerial Systems Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UAVS#NYSE">UAVS</a>), a leading provider of advanced drone and aerial imaging solutions, is proud to announce their Switzerland facility has been recommended to receive ISO 9001 certification by third-party auditors following an intensive review of the facilities Quality Management System. This prestigious certification reflects AgEagle's commitment to excellence, safety, and innovation.
The ISO 9001 standard is widely recognized across all industries and sets rigorous requirements for quality management, customer satisfaction, risk mitigation, safety, and continuous improvement. Earning this certification for the Switzerland facility—home to key research, development, and manufacturing of AgEagle's cutting-edge drone technologies—demonstrates:
<ul>
<li>Unmatched Quality Assurance: The facility meets the highest industry standards for producing reliable drone systems, such as the eBee TAC Public Safety drone and the eBee VISION drone, ensuring precision and performance for worldwide customers. &nbsp;</li>
<li>Operational Excellence: The process highlights AgEagle's dedication to streamlining production and maintaining safety, supporting sustainable farming innovations and bringing new technologies to market &nbsp;</li>
<li>Enhanced Global Trust: Certification strengthens AgEagle's credibility with international clients, including governments and procurement agencies, aligning with the company's growth into Intelligence, Surveillance and Reconnaissance (ISR) marketplaces and public safety operators. &nbsp;</li>
</ul>

UAVS

AgEagle Aerial Systems' Switzerland Facility Recommended To Receive ISO 9001 Certification By Third-Party Auditors Following An Intensive Review Of The Facilities Quality Management System

XAIR

Beyond Air Submits A Premarket Approval Supplement Application To The FDA For LungFit PH II

Press Releases

Cartesian Therapeutics Announces New Employment Inducement Grant

Earnings

Cartesian Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update

Cartesian Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference

Cartesian Therapeutics Announces New Employment Inducement Grants

Cartesian Therapeutics' Descartes-08 Observed to Provide Deep and Sustained Benefits Through Month 12 After a Single Course of Therapy in Phase 2b Myasthenia Gravis Trial

Cartesian Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

Cartesian Therapeutics to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ

Health Care

Cartesian Therapeutics Announces First Participant Enrolled in the Phase 3 AURORA Trial of Descartes-08 in Patients with Myasthenia Gravis

Comments

Cartesian Therapeutics

Cartesian Therapeutics (RNAC) Opciones

Cartesian Therapeutics (NASDAQ:RNAC) Bolsa, Cadena de Opciones

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL